摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-ethylphenyl)butan-1-ol | 183129-81-9

中文名称
——
中文别名
——
英文名称
4-(4-ethylphenyl)butan-1-ol
英文别名
4-(p-Ethyl-phenyl)-butanol
4-(4-ethylphenyl)butan-1-ol化学式
CAS
183129-81-9
化学式
C12H18O
mdl
——
分子量
178.274
InChiKey
UGRFVQJLVCGAKS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    13
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(4-ethylphenyl)butan-1-ol 在 2,2,6,6-tetramethyl-piperidine-N-oxyl 、 sodium hypochlorite碳酸氢钠 作用下, 以 甲苯 为溶剂, 反应 0.5h, 生成 4-(4-Ethylphenyl)butanal
    参考文献:
    名称:
    Structural optimization of 4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepines as antagonists for platelet activating factor: pharmacological contribution of substituents at the 2- and 6-positions of a condensed ring system
    摘要:
    A series of 4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives bearing substituents at the 2- and 6-positions were synthesized, and evaluated in vitro for their inhibitory activity on rabbit platelet aggregation induced by platelet activating factor (PAF) and in vivo for their preventing effect on PAF-induced mortality in mice. The length of alkyl or arylalkyl side chain at the 2-position was responsible for enhancing the affinity for the PAF receptor. The simultaneous substitution at both the 2- and 6-positions resulted in a successful separation of the affinity for the PAF receptor from that for the benzodiazepine (BZ) receptor. Thus, (+/-)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (Y-24180) was confirmed to be a specific antagonist for the PAF receptor and is currently under clinical trials.
    DOI:
    10.1016/0223-5234(96)85877-6
  • 作为产物:
    描述:
    3-(4-乙基苯甲酰)丙酸氢氧化钾 、 sodium tetrahydroborate 、 三氟化硼乙醚一水合肼 作用下, 以 乙二醇 为溶剂, 生成 4-(4-ethylphenyl)butan-1-ol
    参考文献:
    名称:
    Structural optimization of 4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepines as antagonists for platelet activating factor: pharmacological contribution of substituents at the 2- and 6-positions of a condensed ring system
    摘要:
    A series of 4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives bearing substituents at the 2- and 6-positions were synthesized, and evaluated in vitro for their inhibitory activity on rabbit platelet aggregation induced by platelet activating factor (PAF) and in vivo for their preventing effect on PAF-induced mortality in mice. The length of alkyl or arylalkyl side chain at the 2-position was responsible for enhancing the affinity for the PAF receptor. The simultaneous substitution at both the 2- and 6-positions resulted in a successful separation of the affinity for the PAF receptor from that for the benzodiazepine (BZ) receptor. Thus, (+/-)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (Y-24180) was confirmed to be a specific antagonist for the PAF receptor and is currently under clinical trials.
    DOI:
    10.1016/0223-5234(96)85877-6
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF
    申请人:AUGEREAU Jean Michel
    公开号:US20090124624A1
    公开(公告)日:2009-05-14
    The invention concerns 1-amino-phthalazine derivatives of general formula (I): Wherein A, B, L, R, R 1 , R 2 , R 3 , R 4 , R 5 and R 7 are as defined herein. The invention also concerns the preparation of said compounds and their therapeutic use.
    这项发明涉及一般式(I)的1-氨基邻苯二酮衍生物:其中A、B、L、R、R1、R2、R3、R4、R5和R7如本文所定义。该发明还涉及所述化合物的制备及其治疗用途。
  • Potent α-amino-β-lactam carbamic acid ester as NAAA inhibitors. Synthesis and structure–activity relationship (SAR) studies
    作者:Andrea Nuzzi、Annalisa Fiasella、Jose Antonio Ortega、Chiara Pagliuca、Stefano Ponzano、Daniela Pizzirani、Sine Mandrup Bertozzi、Giuliana Ottonello、Glauco Tarozzo、Angelo Reggiani、Tiziano Bandiera、Fabio Bertozzi、Daniele Piomelli
    DOI:10.1016/j.ejmech.2016.01.046
    日期:2016.3
    2-oxo-3-azetidinyl ring as well as on the effect of size and shape of the carbamic acid ester side chain led to the discovery of 3ak, a novel inhibitor of human NAAA that shows an improved physicochemical and drug-like profile relative to 3b. This favourable profile, along with the structural diversity of the carbamic acid chain of 3b, identify this compound as a promising new tool to investigate the potential
    4-环己基丁基-N -[(S)-2-氧杂氮杂环丁-3-基]氨基甲酸酯(3b)是一种有效的,选择性的和系统性的细胞内NAAA活性抑制剂,可在动物模型中产生深远的抗炎作用。在当前的工作中,我们描述了对3-氨基氮杂环丁烷-2-one衍生物的结构-活性关系(SAR)研究,该研究导致了3b的鉴定,并扩展了这些研究以阐明获得有效的结构和立体化学特征。 NAAA抑制。关于2-氧代-3-氮杂环丁烷基环的β-位取代的影响以及氨基甲酸酯侧链的大小和形状的影响的研究导致了3ak的发现。,一种人类NAAA的新型抑制剂,相对于3b而言,它具有改善的理化和类药物特性。这种有利的特性以及3b氨基甲酸酯链的结构多样性,使该化合物成为研究NAAA抑制剂作为治疗疼痛和炎症的潜力的有前途的新工具。
  • CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS
    申请人:The Regents of the University of California
    公开号:US20160068482A1
    公开(公告)日:2016-03-10
    Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.
    本文描述了一些化合物和药物组成物,它们可以抑制N-酰基乙醇胺酸酰化酶(NAAA)。本文还描述了合成这些化合物的方法,以及将它们制成药物组成物的方法。同时,本文还描述了抑制NAAA以维持棕榈酰乙醇胺(PEA)和其他N-酰基乙醇胺(NAE)的水平的方法,这些物质是NAAA的底物,并且在NAE浓度降低的情况下有用。此外,本文还描述了治疗和缓解疼痛、炎症、炎症性疾病和其他疾病的方法,这些疾病中脂肪酸乙醇胺的调节在临床或治疗上是相关的,或者NAE的浓度降低与该疾病有关。
  • [EN] CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS<br/>[FR] DÉRIVÉS DE CARBAMATE D'INHIBITEURS D'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA) À BASE DE LACTAME
    申请人:UNIV CALIFORNIA
    公开号:WO2014144836A3
    公开(公告)日:2014-12-11
  • N-Substituted S-2-aminoethyl thiosulfates as antiradiation agents
    作者:Roger D. Westland、Joyce L. Holmes、Mary Lou Mouk、Douglas D. Marsh、Richard A. Cooley、John R. Dice
    DOI:10.1021/jm00312a019
    日期:1968.11
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐